{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T15:23:57Z","timestamp":1773415437300,"version":"3.50.1"},"reference-count":96,"publisher":"Wiley","issue":"8pt1","license":[{"start":{"date-parts":[[2008,7,10]],"date-time":"2008-07-10T00:00:00Z","timestamp":1215648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2008,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The main goals of chronic hepatitis B treatment should be the long\u2010term suppression of viral replication to minimize disease progression and the risk for the development of hepatocellular carcinoma. Treatment end\u2010points, depending on surrogate markers alone, in particular hepatitis B e\u2010antigen seroconversion, may not be ideal for patients who acquire the disease early in life.<\/jats:p><jats:p>Currently\u2010available drugs include interferons and oral nucleoside\/nucleotide analogs. Although interferon therapy provides a finite treatment period, a significant proportion of patients may not respond, and long\u2010term outcome is inconclusive. Long\u2010term efficacy has been demonstrated for both lamivudine and adefovir. However, prolonged nucleoside\/nucleotide analog therapy is associated with the emergence of drug\u2010resistant mutations. Therefore, nucleoside\/nucleotide analogs with a high genetic barrier and potent antiviral activity, such as entecavir, should be used to reduce the chance of developing drug\u2010resistant mutations. Drugs with a low genetic barrier, including lamivudine and telbivudine, should be used in conjunction with early testing for antiviral response. This can predict favorable outcomes in the long term. The early detection of drug\u2010resistant mutations should prompt clinicians to either add or switch to another agent with a different drug\u2010resistance profile. There are currently no treatment models in the use of combination or sequential therapy in treatment\u2010na\u00efve patients.<\/jats:p><jats:p>To date, long\u2010term treatment appears to be the most effective option. Despite recent advances made with better understanding on the natural history of chronic hepatitis B infection and with newer antiviral drugs available, challenges remain with respect to treatment criteria, treatment end\u2010points, and duration of treatment.<\/jats:p>","DOI":"10.1111\/j.1440-1746.2008.05400.x","type":"journal-article","created":{"date-parts":[[2008,7,10]],"date-time":"2008-07-10T07:21:19Z","timestamp":1215674479000},"page":"1182-1192","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["New paradigms for the treatment of chronic hepatitis B"],"prefix":"10.1111","volume":"23","author":[{"given":"James","family":"Fung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching\u2010Lung","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man\u2010Fung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,31]]},"reference":[{"key":"e_1_2_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199712113372406"},{"key":"e_1_2_3_3_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.89.1.14"},{"key":"e_1_2_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.05.016"},{"key":"e_1_2_3_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21513"},{"key":"e_1_2_3_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-4-199308150-00011"},{"key":"e_1_2_3_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2003.00450.x"},{"key":"e_1_2_3_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043470"},{"key":"e_1_2_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00997.x"},{"key":"e_1_2_3_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.01006.x"},{"key":"e_1_2_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00088-07"},{"key":"e_1_2_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2006.01257.x"},{"key":"e_1_2_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2005.00566.x"},{"key":"e_1_2_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl385"},{"key":"e_1_2_3_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.46.4.562"},{"key":"e_1_2_3_16_2","first-page":"279","article-title":"Long\u2010term follow\u2010up of Japanese patients with chronic hepatitis B treated with interferon\u2010alpha","volume":"16","author":"Truong BX","year":"2005","journal-title":"Int. J. Mol. Med."},{"key":"e_1_2_3_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.25273"},{"key":"e_1_2_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.08.021"},{"key":"e_1_2_3_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199807093390201"},{"key":"e_1_2_3_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199910213411702"},{"key":"e_1_2_3_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033364"},{"key":"e_1_2_3_22_2","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/135965350701200816","article-title":"Long\u2010term lamivudine therapy reduces the risk of long\u2010term complications of chronic hepatitis B infection even in patients without advanced disease","volume":"12","author":"Yuen MF","year":"2007","journal-title":"Antivir. Ther."},{"key":"e_1_2_3_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510270628"},{"key":"e_1_2_3_24_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50117"},{"key":"e_1_2_3_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020681"},{"key":"e_1_2_3_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021812"},{"key":"e_1_2_3_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20939"},{"key":"e_1_2_3_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042957"},{"key":"e_1_2_3_29_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2005.20.5.821"},{"key":"e_1_2_3_30_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.10.051"},{"key":"e_1_2_3_31_2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/135965350701200109","article-title":"Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population","volume":"12","author":"Fung J","year":"2007","journal-title":"Antivir. Ther."},{"key":"e_1_2_3_32_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.08.079"},{"key":"e_1_2_3_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03567.x"},{"key":"e_1_2_3_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.05093.x"},{"key":"e_1_2_3_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21534"},{"key":"e_1_2_3_36_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.09.020"},{"key":"e_1_2_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00939-9"},{"key":"e_1_2_3_38_2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/135965350701200309","article-title":"In vitro susceptibility of adefovir\u2010associated hepatitis B virus polymerase mutations to other antiviral agents","volume":"12","author":"Qi X","year":"2007","journal-title":"Antivir. Ther."},{"key":"e_1_2_3_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051287"},{"key":"e_1_2_3_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051285"},{"key":"e_1_2_3_41_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.37058"},{"key":"e_1_2_3_42_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.08.025"},{"key":"e_1_2_3_43_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.06.055"},{"key":"e_1_2_3_44_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.04.007"},{"key":"e_1_2_3_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21422"},{"key":"e_1_2_3_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.9.3498-3507.2004"},{"key":"e_1_2_3_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00833-06"},{"key":"e_1_2_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastro.2005.05.053"},{"key":"e_1_2_3_49_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-11-200712040-00183"},{"issue":"1","key":"e_1_2_3_50_2","first-page":"222A","article-title":"Two\u2010year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs. lamivudine","volume":"44","author":"Lai CL","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_3_51_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200727010-00003"},{"key":"e_1_2_3_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040431"},{"key":"e_1_2_3_53_2","first-page":"S748A","article-title":"Telbivudine (LdT) vs lamivudine for chronic hepatitis B: first year results from the International Phase III GLOBE Trial (LB Abstract 01)","volume":"42","author":"Lai CL","year":"2005","journal-title":"Hepatology"},{"key":"e_1_2_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.05.037"},{"key":"e_1_2_3_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21189"},{"key":"e_1_2_3_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2006.11.014"},{"key":"e_1_2_3_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2005.01134.x"},{"key":"e_1_2_3_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20110"},{"key":"e_1_2_3_59_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840070424"},{"key":"e_1_2_3_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(87)90250-2"},{"key":"e_1_2_3_61_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013215"},{"key":"e_1_2_3_62_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03390.x"},{"key":"e_1_2_3_63_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.065136"},{"key":"e_1_2_3_64_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.16665"},{"key":"e_1_2_3_65_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-5-29"},{"issue":"1","key":"e_1_2_3_66_2","first-page":"653A","article-title":"Treatment\u2010induced HBeAg seroconversion is a poor therapeutic endpoint","volume":"46","author":"Lim SG","year":"2007","journal-title":"Hepatology"},{"key":"e_1_2_3_67_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-1-200707030-00010"},{"key":"e_1_2_3_68_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.04938.x"},{"key":"e_1_2_3_69_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.1.65"},{"key":"e_1_2_3_70_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.33588"},{"issue":"4","key":"e_1_2_3_71_2","first-page":"640A","article-title":"HBV viral load less than 104 copies\/ml is associated with significant risk of hepatocellular carcinoma in chronic hepatitis B patients: an update from the R.E.V.E.A.L. HBV study","volume":"46","author":"Iloeje U","year":"2007","journal-title":"Hepatology"},{"key":"e_1_2_3_72_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.36026"},{"key":"e_1_2_3_73_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.10.048"},{"key":"e_1_2_3_74_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21702"},{"key":"e_1_2_3_75_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20240"},{"key":"e_1_2_3_76_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280130"},{"key":"e_1_2_3_77_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38050.593634.63"},{"key":"e_1_2_3_78_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-1-200207020-00006"},{"key":"e_1_2_3_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2003.12.040"},{"key":"e_1_2_3_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2007.07.022"},{"key":"e_1_2_3_81_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21585"},{"key":"e_1_2_3_82_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21724"},{"key":"e_1_2_3_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.1995.tb00010.x"},{"issue":"4","key":"e_1_2_3_84_2","first-page":"583A","article-title":"Long\u2010term beneficial outcome of Chinese asymptomatic patients with HBeAg\u2010positive chronic hepatitis B on continuous lamivudine therapy: 7\u2010year experience","volume":"42","author":"Yuen M","year":"2005","journal-title":"Hepatology"},{"key":"e_1_2_3_85_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00866.x"},{"key":"e_1_2_3_86_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02887.x"},{"issue":"4","key":"e_1_2_3_87_2","first-page":"673A","article-title":"Twenty\u2010four weeks therapy with peginterferon alfa\u20102a is similar to 48\u2003weeks therapy in patients with HBeAg positive chronic hepatitis B and good predictor of response","volume":"46","author":"Rezzonico L","year":"2007","journal-title":"Hepatology"},{"issue":"5","key":"e_1_2_3_88_2","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1002\/hep.1840360730","article-title":"Side effects of therapy of hepatitis C and their management","volume":"36","author":"Fried MW","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_3_89_2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1177\/135965350601100614","article-title":"Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy","volume":"11","author":"Liaw YF","year":"2006","journal-title":"Antivir. Ther."},{"key":"e_1_2_3_90_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.27563"},{"issue":"2","key":"e_1_2_3_91_2","first-page":"S17","article-title":"Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB)","volume":"42","author":"Locarnini S","year":"2005","journal-title":"J Hepatol."},{"issue":"2","key":"e_1_2_3_92_2","first-page":"S175","article-title":"On\u2010treatment predictors of sustained biochemical and virological response in patients with HBeAg\u2010negative chronic hepatitis B (CHB) treated with peginterferon alpha\u20102a (40\u2003kDa) (PEGASYS)","volume":"42","author":"Farci P","year":"2005","journal-title":"J. Hepatol."},{"key":"e_1_2_3_93_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21939"},{"key":"e_1_2_3_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.05.004"},{"key":"e_1_2_3_95_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2006.04499.x"},{"key":"e_1_2_3_96_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03272.x"},{"key":"e_1_2_3_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(06)80483-6"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1746.2008.05400.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1746.2008.05400.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:04:54Z","timestamp":1738281894000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1746.2008.05400.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,31]]},"references-count":96,"journal-issue":{"issue":"8pt1","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["10.1111\/j.1440-1746.2008.05400.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1746.2008.05400.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,31]]},"assertion":[{"value":"2008-07-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}